Supported by a strong global patent asset and collaborative relationships with the Departments of Defence in the UK, Canada and Australia, PlantForm Corporation is seeking $25 million in capital to accelerate its growth, research and development and clinical trial process.
Investment Opportunity in PlantForm Corporation
PLANTFORM CO., LTD.
SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) — US Capital Global Securities LLC, an SEC-registered affiliate of well-known global financial group US Capital Global, is pleased to offer accredited investors a unique opportunity to participate in an investment round of up to $25 million in PlantForm Corporation (“PlantForm” or the “Company”) Based in Toronto, Canada, PlantForm is at the forefront of innovative biotechnology, developing plant-based medical countermeasures to major terrorist threats such as ricin and sarin gas, as well as other important medical breakthroughs.
Unique In vivoXPRESS® technology uses genetic engineering Nicotiana benthamiana PlantForm uses plants as a source of raw materials to rapidly produce high-value biosimilars and specialty antibody protein drugs at dramatically reduced costs – up to 90% over traditional methods. The company’s portfolio includes biosimilars of market-leading drugs such as Keytruda® for oncology and Lucentis® for age-related macular degeneration, with applications spanning novel nerve agent countermeasures.
“PlantForm is at an important inflection point in our international growth as we continue to develop lower-priced versions of current drugs for the multi-billion dollar biosimilar market,” said Don Stewart, PhD, PlantForm’s president and CEO. “We have already signed a high-value contract with the Brazilian government to develop biosimilar Keytruda® and other biological medicines. PlantForm has completed projects funded by the Defense Advanced Research Projects Agency and the Bill & Melinda Gates Foundation. Additionally, we have been awarded a contract by Canada to develop a swine vaccine and are actively pursuing global commercialization.”
“PlantForm’s exciting pipeline of cutting-edge plant-based products includes next-generation animal vaccines, cost-effective and life-saving biosimilar drugs, breakthrough antibodies for the treatment of HIV, and counter-terrorism solutions for chemical warfare,” said Lisa Turk, senior vice president at US Capital Global. “The company’s portfolio of biological medicines produced using its plant-based system is much more efficient and less costly to manufacture for new indications in new markets. For opportunity-seeking investors, PlantForm presents a compelling proposition and is currently inviting qualified investors to participate in its unique $25 million public offering.”
about PLANTFORM CO., LTD.
PlantForm Corporation is a biopharmaceutical company focused on producing high-value antibody and protein drugs and vaccines at low cost using its proprietary technology. In vivoXPRESS® Plant-based manufacturing platform. In vivoXPRESS® Plant expression systems produce biological medicines at significantly lower cost than standard mammalian cell systems. The platform is fast (producing medicines in as little as six weeks), versatile and easily scalable. PlantForm’s pipeline includes an innovative antidote for ricin exposure and a biosimilar version of the branded biological medicine Lucentis.® and Keytruda®For more information, visit www.plantformcorp.com.
About US Capital Global
US Capital Global Securities LLC (USCGS) serves as the FINRA member broker-dealer division of US Capital Global, specializing in facilitating growth stage investing. Since 1998, US Capital Global has been dedicated to providing sophisticated investment opportunities to middle market companies and investors. For more information about US Capital Global Securities or this investment opportunity, please contact Lisa Terk, Senior Vice President, at lterk@uscapital.com. Alternatively, please call +1 415-889-1026.
Disclaimer: USCGS or its affiliates may provide advice, receive compensation, have other business relationships with, and from time to time acquire, hold, or sell positions in the securities of any issuers mentioned herein. Any offers or solicitations will be made only pursuant to a confidential private placement memorandum. The USCGS CRS form is available at Click here for details.
Attachments
CONTACT: Vanessa Guajardo US Capital Global +1 415 889 1010 media@uscapglobal.com
